NovoCure Limited
NVCR
$15.58
-$0.25-1.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -40.02% | 38.22% | 41.87% | 26.95% | -26.21% |
| Total Depreciation and Amortization | 19.74% | -12.31% | 5.03% | 3.42% | -11.86% |
| Total Amortization of Deferred Charges | 12.06% | -- | -- | -- | 5.47% |
| Total Other Non-Cash Items | 1,076.74% | 7.93% | -14.94% | -8.18% | -75.86% |
| Change in Net Operating Assets | -79.20% | 164.32% | 62.75% | -8,971.53% | 129.48% |
| Cash from Operations | 76.29% | 153.72% | 92.44% | -88.76% | -292.72% |
| Capital Expenditure | -31.10% | -47.29% | -65.14% | -93.56% | -6.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -112.60% | -14.83% | -5,110.94% | 191.94% | 186.59% |
| Cash from Investing | -122.55% | -40.94% | -2,594.39% | 199.22% | 176.92% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -430,333.33% | -- | 100.00% |
| Issuance of Common Stock | 40.58% | -91.46% | -55.92% | -95.91% | -44.10% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 40.58% | -91.46% | 1,063.92% | -95.91% | -43.99% |
| Foreign Exchange rate Adjustments | -164.00% | 189.69% | -492.31% | -236.59% | 29.03% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -126.85% | 2,213.65% | -891.32% | 203.37% | 167.12% |